Perrigo invests in the Nepentes portfolio
Ten post jest także dostępny w języku:
polski
The Office of Competition and Consumer Protection has received an application for a permit to acquire some of the products belonging to the portfolio of Nepentes Pharma Sp. z o.o., part of the Sanofi group. Under the concentration, Perrigo will become their owner.
Portfolio expanded by key brands
The acquisition concerns three of Sanofi’s key skincare and hair loss brands OTC. These will include Emolium, Iwostin and Loxon. The sales of these brands in Poland in the pharmacy cosmetics and other OTC dermatological products segment in 2019 reached over PLN 100m in the pharmacy segment alone.
As part of the planned transaction, Perrigo will acquire assets related to the promotion and distribution of these products. This is another acquisition on the OTC segment this year.
Perrigo strengthens on the OTC market in Poland
Perrigo’s portfolio includes OTC drugs, medical equipment, cosmetics and dietary supplements. In 2019, the company was ranked among the 20 largest manufacturers on the pharmacy OTC products market in Poland. Important Perrigo brands include such products as Undofen, Tymianek and Podbial, Solpadeine, Dermosan, Capivit, NiQuitin and Lactacyd.
The acquisition of products from the Nepentes portfolio is part of the company’s development strategy in the field of OTC dermatological products and is to apply to the entire Eastern Europe.
